1 December 2020 in Journal of Stroke and Cerebrovascular Diseases
13 October 2021 in Journal of the Neurological Sciences
1 July 2021 in QJM: An International Journal of Medicine
Neuralgic amyotrophy is commonly preceded by an antecedent event such as infection, surgery and less commonly vaccinations. COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273) may be, albeit rare, a trigger of neuralgic amyotrophy. All patients recovered considerably, further reiterating that the benefits of mRNA vaccines outweigh adverse events.
10 November 2022 in QJM: An International Journal of Medicine
GCGeraldine Jiangyan Chen
+8
Summary: Background: Individuals who suffered a neurological adverse event after the Coronavirus disease (COVID-19) vaccine could hesitate and defer reimmunization.Aim: We examine the risk of recurrence following reimmunization among patients who developed a neurological event after the first dose of the COVID-19 mRNA vaccine.Design: Observational study.Methods: Individuals who developed an adjudicated neurological adverse event (based on Brighton Collaboration criteria) within 6 weeks of the first dose of the COVID-19 vaccine requiring hospitalization were enrolled into a multicenter national registry in Singapore. Neurological recurrence, defined by the development of another neurological event within 6 weeks of the second vaccine dose, was reviewed. Clinical characteristics were compared between patients who chose to proceed or withhold further vaccination, and between those who received timely (3–6 weeks) or delayed (>6 weeks) reimmunization.Results: From 235 patients (median age, 67 years; 63% men) who developed an adjudicated neurological event after their first dose of mRNA vaccine between 30 December 2020 and 20 April 2021, 181 (77%) chose to undergo reimmunization. Those who decided against reimmunization were older (median age, 74 vs. 66 years) and had greater physical disability following their primary neurological event (46% vs. 20%, P < 0.001). Patients who suffered greater physical disability were three times more likely to delay their reimmunization (odds ratio 3.36, 95% confidence interval: 1.76–6.40). Neurological recurrence was observed in only four individuals (three with seizures and one with myasthenia gravis exacerbation).Conclusions: A prior neurological event should not necessarily preclude reimmunization and the decision to proceed with reimmunization should consider the overwhelming benefits conferred by vaccination toward ending this pandemic.
21 February 2020 in Case Reports in Neurological Medicine
GTGenevieve Lynn Yu Tan-Yu
Chronic immune sensory polyradiculopathy (CISP) is an uncommon and treatable inflammatory disorder of the proximal sensory nerve roots. Patients typically present with severe sensory ataxia, normal motor examination, unsteady gait, and normal nerve conduction studies (NCS). We describe an elderly man who presented with a two-week history of progressive numbness of both legs and recurrent falls. He had hyporeflexia, normal strength, severe proprioceptive, and vibration sense loss in both lower limbs and was unable to stand or walk because of severe sensory ataxia. The NCS and MR scan of the spine were normal. Tibial somatosensory evoked potentials revealed proximal conduction defect and localized the pathology to the lumbar sensory nerve roots proximal to the dorsal root ganglion. Cerebrospinal fluid showed cytoalbuminergic dissociation suggestive of inflammation. CISP was diagnosed; he was given aggressive immunotherapy consisting sequentially of corticosteroids with mycophenolate mofetil and three cycles of intravenous immunoglobulin after which he regained independent mobility. Unlike previous reports where patients presented months-years after symptom onset and improved after single-line immunotherapy, our patient presented fairly acutely and made dramatic improvement only after aggressive combination therapy. We urge physicians to recognize this uncommon neurologic cause of sensory ataxia where early aggressive treatment is crucial for better functional outcomes.
12 February 2022 in QJM: An International Journal of Medicine
NDN. Wijesoma Dona Manuwelge Dona
N. Wijesoma Dona Manuwelge Dona
A previously well 27-year-old Bangladeshi man developed insidious left-hand weakness for 6 days. Physical examination showed marked wasting over the left forearm and hand muscles with sparing of the brachioradialis muscle. Atrophy of the hypothenar eminence was more prominent compared to thenar eminence, suggestive of reverse split hand syndrome ( Figure 1A). Power testing revealed unilateral left C7-T1 segmental weakness and normal sensation. Nerve conduction study and electromyography corroborated these findings which were most marked in the ulnar innervated muscles. Magnetic resonance imaging (MRI) of the cervical spine revealed focal cervical cord atrophy with C5–7 intramedullary hyperintense signal in neutral position and anterior displacement of the posterior dura with prominent posterior epidural space and flow voids in flexion position ( Figure 1B). He was diagnosed with Hirayama disease and advised to apply a hard cervical collar to prevent neck flexion injury.